自20世纪初以来，随着青霉素和链霉素在1940年代的分离，现代抗感染药物发展势头强劲。由于早期药物发现的巨大成功，许多传染病被成功地预防和根除。然而,这个最初的希望是错误的，和病原体进化成为对人类健康的重大威胁。耐药性的发展是自然选择的无情压力的结果，需要鉴定新的药物靶标并创建绕过现有耐药机制的化学疗法。脂肪酸生物合成（FAS）是细菌生长和发育过程中的重要代谢机制。参与该生物合成途径的几种关键酶已被鉴定为新抗菌剂的潜在靶标。在大肠杆菌(E.大肠杆菌)，这一途径已被广泛研究。本审查的重点是KasA的发展进展，KasB,和FabH抑制剂作为单一治疗抗生素。
Since the early twentieth century, with the isolation of penicillin and streptomycin in the 1940s, the modern era of anti-infective drug development has gained momentum. Due to the enormous success of early drug discovery, many infectious diseases were successfully prevented and eradicated. However, this initial hope was wrongheaded, and pathogens evolved as a significant threat to human health. Drug resistance develops as a result of natural selection\'s relentless pressure, necessitating the identification of new drug targets and the creation of chemotherapeutics that bypass existing drug resistance mechanisms. Fatty acid biosynthesis (FAS) is a crucial metabolic mechanism for bacteria during their growth and development. Several crucial enzymes involved in this biosynthetic pathway have been identified as potential targets for new antibacterial agents. In Escherichia coli (E. coli), this pathway has been extensively investigated. The present
review focuses on progress in the development of Kas A, Kas B, and Fab H inhibitors as mono-therapeutic antibiotics.
